Related Experiment Videos
Cerebrospinal fluid hydroxylase cofactor in schizophrenia
Psychiatry Research
|April 1, 1982
Summary
Cerebrospinal fluid pterin cofactor levels did not differ between schizophrenia patients and controls. However, platelet monoamine oxidase activity correlated with pterin levels in male patients and female controls, suggesting a link in specific groups.
Area of Science:
- Neuroscience
- Biochemistry
- Psychiatry
Background:
- Schizophrenia is a complex psychiatric disorder.
- Monoamine neurotransmitters like dopamine and norepinephrine are implicated in schizophrenia pathophysiology.
- Pterin cofactor is crucial for synthesizing these monoamines.
Purpose of the Study:
- To investigate cerebrospinal fluid pterin cofactor levels in schizophrenia.
- To explore the relationship between pterin cofactor and monoamine oxidase activity in schizophrenia.
Main Methods:
- Cerebrospinal fluid (CSF) pterin cofactor levels were measured.
- Platelet monoamine oxidase (MAO) activity was assessed.
- Off-medication schizophrenic patients and normal controls were studied.
Main Results:
- No significant differences in CSF pterin cofactor levels were observed between schizophrenic patients and controls.
- Platelet MAO activity showed a significant correlation with pterin levels in male schizophrenic subjects.
- A significant correlation between platelet MAO activity and pterin levels was also found in female control subjects.
Conclusions:
- CSF pterin cofactor levels do not appear to be significantly altered in schizophrenia.
- Platelet MAO activity may be linked to pterin cofactor levels in specific demographic groups within schizophrenia and control populations.